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Summary: Vasopressin receptor expression on LLC-PKrcells (a porcine renal tubular cell line) during cell
culture is still not fully understood. We studied receptor expression using a novel vasopressin analogue with
high specific radioactivity ([125I][8-/?-hydroxy-phenylpropionyl]-lys8-vasopressin, 74EBq/mol (2000 Ci/mmol)).
cells were grown in monolayers for 1 to 6 days. Scatchard analysis performed with membranes of
cells revealed a single binding site with a binding constant (Kd) of 0.46 ± 0.04 nmol/1. During cell
culture, the binding constant (Kd) was not altered, but receptor density increased significantly (21 115 ± 645
receptors per cell, day 2; 42315 ± 1512 receptors per cell, day 6). A receptor occupancy of about 30% was
found to be associated with a cAMP stimulation of 50%. The receptor reserve might be even higher because,
by using a highly specific oxytocin antagonist, we found that 20% of the occupied [125I][8-/?-hydroxy-
phenylpropionyl]-lys8-vasopressin-binding sites are oxytocin receptors. For Iys8-vasopressin receptor studies,
great care has to be taken to examine cells in identical culture phases.
Introduction . , .
 n ,vasopressin receptor expression during cell culture.
LLC-PKi cells, an established porcine renal cell line Furthermore, we analysed the relationship between
(1) with polar epithelial cell characteristics maintained lys8-vasopressin binding to its receptor on LLC-PKi
in culture, has been shown to express some hormone cells and the Iys8-vasopressin-induced cAMP genera-
receptors, e. g. for atria! natriuretic peptide and lys8- tion.
vasopressin. LLC-PKi cells have been used as a model
to study peptide hormone/hormone-receptor interac-
tions (e. g. receptor downregulation) in vitro. Vaso- Materials and Methods
pressin, like other peptide hormones, performs its
physiological function by binding to cell-surface re-
ceptors in association with a specific guanine-nucle- We used LLC-PK, cells (a porcine renal tubular cell line, ATCC
otide-binding pro«,, These actions in «he kidney are ^^^K^^^^Kf^S
mediated by the adenylate-cyclase-coupled V2-recep- (1); the [l25l]cAMP assay was from Amersham Int. (Bucking-
tor subtype (2, 3). However, little is known about hamshire, England). Lys*-vasopressin was obtained from Pen-
•normal- vasopressin receptor expression and vaso- £* !±5± 2 3 -±S
pressm-induced cAMP generation during cell culture. from Merck (Darmstadt, Germany) and Sigma (Munich, Ger-
Therefore, we used the vasopressin analogue [125I][8- many). The oxytocin antagonist, [l25I]d(CH2)5(Tyr(Me)2,Tyr4,
„hydroxy-phenylpropionyiHys'-vasopressin pre-
pared recently in our laboratory (4, 5) to analyse (14).
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Cell cu l tu re
LLC-PK, cells were grown in monolayers for 1 to 8 days in 75
cm2 culture flasks containing Hani's P12 medium (Seromed,
Germany), fetal calf serum (volume fraction 0.06) (Seromed,
Germany), 2mmol/l L-glutamine and antibiotics (100 mg/1
streptomycin and 100 · 103 U/l penicillin). The cells were cul-
tured at 37 °C in a humidified CO2 incubator (95% air and 5%
CO2). 20000 cells were sown per cm2 on the first day of
cultivation. The medium was changed every 48 hours. Viability
was estimated by the trypan blue method. Cell counts per-
formed with the Neubauer-counting system were used to estab-
lish the growth pattern.
Preparat ion of crude plasma membrane fractions
Partially purified membranes from LLC-PK ι cells were pre-
pared as previously described (4). Briefly, cells were detached
by incubation for 30 min at 37 °C in 50 mmol/1 Tris, 0.15 mol/1
NaCl, l g/l Na2EDTA, pH 7.4. Afterwards cells were lysed
using a hypotonic buffer (5 mmol/1 Tris-HCl, 1 mmol/1 EDTA
and 3 mmol/1 MgCl2, pH 7.4), and finally the lysate was ho-
mogenized. The homogenate was centrifuged at 2000 g for 10
min and the pellet thus obtained was washed twice in assay
buffer and immediately processed.
Binding studies
Plasma membranes of LLC-PK! cells (150 μg/tube) were in-
cubated with [125I][8-/7-hydroxy-phenylpropionyl]lys8-vasopres-
sin (5000—2000000 counts per min per tube, which is equiv-
alent to 0.012 nmol/l—4 nmol/1; incubation volume was 150 μΐ)
for "hot saturation" studies. For "cold saturation" studies, we
used 30000 counts per min tracer and increasing amounts of
lys8-vasopressin. Unless otherwise stated, binding studies were
performed at 22 °C for 90 min as described previously (4, 5).
Assay buffer for binding studies contained 1 g/1 bacitracin, 100
mmol/1 Tris, 5 mmol/1 MgCl2, and 1 g/1 bovine serum albumin,
pH 7.8. Non-specific binding was determined by addition of
3.3 mmol/1 lys8-vasopressin. Two millilitres of cold binding
buffer were added. After separation of free and bound radio-
activity by centrifugation at 3000 g for 10 min at 4°C, the
membranes were washed twice in cold binding buffer.
[125I]cAMP assay
cAMP production in LLC-PKrcell monolayers was determined
in 96-well culture plates. The culture medium was aspirated
and washed with assay buffer consisting of 150 mmol/1 NaCl,
5 mmol/1 KC1, 5 mmol/1 MgCl2, 1 mmol/1 CsCl2, 1 mmol/1 3-
w -butyl-1-methylxanthine, 20 mmol/1 Tris-HCl, 1 g/1 bovine
serum albumin, and 1 g/1 bacitracin, pH 7.8. The buffer was
than aspirated and replaced with 150 μΐ of assay buffer con-
taining Iys8-vasopressin at 22 °C; the incubation volume was
150 μΐ. After 120 min incubation, 0.25 ml cold ethanol (100%)
was added to lyse the cells and stop cAMP production. After
centrifugation (41 000 g, 4 °C), the medium was further diluted
in radioimmunoassay buffer for the messurement of cAMP
using a radioimmunoassay ([l25I]cAMP assay from Amersham
Int., Buckinghamshire, England).
The binding constant (Kd) did not change and was
0.46 ± 0.04 nmol/1 between day 2 and day 6 (fig. 1).
The receptor density per cell (fig. 2) increased mark-
edly until day 6 (achievement of confluence) and it
decreased markedly when ' hyperconfluence was
reached (data not shown). Cell size increased only
slightly from day 2 after seeding to day 6 after seeding
(about 9%) and did not correlate with the number of
receptors per cell (data not shown). However, the
picture changes when the number of receptors is re-
lated to the protein content. Figure 3 demonstrates
the changes in receptor density during cell cultivation
expressed as receptors per mg protein. We also com-
pared the binding of [125I]d(CH2)5(Tyr(Me)25Tyr45Tyr-
NH^-oxytocin, an oxytocin antagonist (14), with the
binding of [125I][8-/?-hydroxy-phenylpropionyl]-lys8-
vasopressin to LLC-PK! cell monolayers on day
6 after seeding. The receptor density of
[125]d(CH2)5(Tyr(Me)?,Tyr4,Tyr-NH!)-oxytocin was
about 20% compared with the receptor density of
[125I][8-/7-hydroxy-phenylpropionyl]-lys8-vasopressin
(fig. 4). About 20% of the [125I][8-/?-hydroxy-phenyl-
propionyl-lys8-vasopressin binding sites could be re-
placed by [I25I]d(CH2)5(tyr(Me)2,Tyr4,Tyr-NH!)-oxy-
tocin (data not shown).
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Fig. 1. Binding of [I25i][8-/?-hydroxy-phenylpropibnyl]-lys8-va-
sppressin to LLC-PKt cell monolayers on day 2 (filled
circles) and day 6 (open triangles) after seeding. The
data were analysed according to Scatchard (insert).
Binding assays (cold saturation) were carried out as
described under Materials and Methods. Values are
means from 2 individual determinations.
Results
[125I][8-/?-hydroxy-phenylpropionyl]-lys8-va-
sopressin binding studies
The confluence was 39% on day 2, 79% on day 3,
95% on day 4, 97% on day 5 and 100% on day 6.
cAMP production in response to vasopressin
• Addition of (8-lysine>vasopressin to LLC-PK! cell
monolayers on day 6 (100% confluence) was followed
by a dose-dependent increase ;of intracellular cAMP
accumulation (fig. 5). Lys8-vasopressin (10 mmol/1)
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Fig. 2. Receptor density during cell cultivation expressed as
receptors per cell. Values are means from 5 individual
determinations ± S. D.
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Fig. 3. Receptor density during cell cultivation expressed as
receptors per mg of protein. Values are means from 5
individual determinations ± S. D.
increased intfacellular cAMP to concentrations 16
times higher than the baseline cAMP production rate.
The lowest lys^vasopressin concentration leading to
a significant intracellular cAMP increase was 0.07
nmol/l. The binding constant (Kd), analysed in the
same experiment was 0.48 nmol/l.
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Fig. 4. Binding of [I25I][8-/?-hydroxy-phenylpropionyl]-lys8-va-
sopressin (open triangles) and [l25l\d(CH2)s
(Tyr(Me)2,Tyr4,Tyr-NH2)-oxytocin (filled circles) to
LLC-PKj cells monolayers on day 6 after seeding. The
data were analysed according to Scatchard (insert).
Binding assays (hot saturation) were carried out as
described under Materials and Methods. Values are
means from 3 individual determinations.
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Fig. 5. Accumulation of cAMP in lyss-vasopressin-treated
LLC-PK, cells (filled circles) and Iys8-vasopressin bind-
ing to LLC-PKi cells (open triangles). The cAMP assay
and the binding studies (cold saturation) were carried
out as described under Materials and Methods. Values
are means from 2 individual determinations.
Discussion
The vasopressin V2 receptor has been cloned previ-
ously and is a 370-amino-acid protein linked to aden-
ylate cyclase with seven transmembrane domains and
the characteristics of a G-protein-coupled receptor (6,
7). However, little is known about vasopressin-recep-
tor expression during cell culture. Cell culture does
not influence the binding constant of the vasopressin
receptor (fig. 1), so that a modification of this receptor
(altered phosphorylation or glycosylation) during cul-
tivation is unlikely. On the other hand, the number
of binding sites per cell is clearly related to confluence
(fig. 2). Known regulators for the number of vaso-
pressin binding sites per cell are vasopressin (homol-
ogous downregulation) (9) and other hormones or
drugs (heterologous sensitation or desensitation)
(6 — 8, 10). Growth behaviour in cell culture has not
previously been reported to influence the expression
of vasopressin receptors. The cell-to-cell interaction
mechanisms (secreted autoregulatory factors or direct
ur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 5
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cell-to-cell interactions) regulating the number of va-
sopressin receptors are unknown. The ratio of the
number of receptors to the protein content is not a
suitable quantity for investigation, because marked
changes occur in the total cellular protein content
during cell culture (fig. 3). Strictly identical culture
phases and culture age are therefore important when
studying the regulation of vasopressin receptors. An
examination of the dose-effect relation between va-
sopressin - or [125I][8-/?-hydroxy-phenylpropionyl]-
lyss-vasopressin (fig. 5) — binding and receptor-me-
diated cAMP stimulation showed that a receptor oc-
cupancy of 30% is associated with a cAMP stimula-
tion of 50%. But we should keep in mind that the
relationship between vasopressin binding and cAMP
formation is influenced by many other events, e. g.
(i) lateral mobility of the hormone-receptor complex
in the plasma membrane,
(ii) receptor internalization,
(iii) G-protein-receptor interaction, and
(iv) G-protein-adenylate cyclase interaction (11, 12).
However, receptor reserve (under the conditions we
used) might be even higher, since LLC-PKi cells ex-
press oxytocin receptors (13) and we found that ap-
proximately 20% of the occupied receptors are oxy-
tocin receptors (fig. 4). [I25I][8->r-hydroxy-phenylpro-
pionyl]-lys*-vasopressin is also an oxytocin receptor
ligand (data not shown). The oxytocin receptor does
not stimulate cAMP formation and mainly interacts
with the G-protein-mediated phosphatidylinositol
pathway (13 — 15). Therefore, further studies should
be performed to examine whether the relationship
between vasopressin binding and receptor-mediated
cAMP stimulation is also associated with the conflu-
ence of LLC-PK! cells in cell culture.
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